創薬インフォマティクス市場：用途別、機能別、エンドユーザー別、地域別（2026～2032年）

創薬インフォマティクス市場の評価（2026～2032年）

創薬の複雑化、医薬品開発期間の短縮化、オーダーメイド治療の重視など、創薬インフォマティクスに対する需要は拡大しています。ゲノミクス、プロテオミクス、人工知能などの技術の進歩により、研究者は大量のデータを収集・分析できるようになり、これらの情報を整理・解釈するためのインフォマティクス・ツールの需要が高まっています。市場規模は2024年に34億1,000万米ドルを超え、2032年には約75億7,000万米ドルに達します。

特定の疾患や患者集団に的を絞った医薬品の開発が重視されるようになり、より高度な創薬インフォマティクス・システムに対する需要が高まっています。費用対効果が高く効率的な創薬インフォマティクスに対する需要の高まりが、2026年から2032年までのCAGR 11.57%での市場の成長を可能にしています。

創薬インフォマティクス市場定義/概要

創薬インフォマティクスは、創薬と薬剤開発のプロセスを改善するための計算ツールやアプローチの応用です。この学際的な分野は、データ管理、バイオインフォマティクス、ケモインフォマティクス、高度な分析ツールを用いて、生物学的データ、化学的特性、薬物相互作用を調べます。研究者が有望な薬物候補を見つけ、その有効性と安全性を予測し、化学構造を最適化するのに役立ちます。アプリケーションには、仮想化合物ライブラリーのスクリーニング、定量的構造活性相関（QSAR）モデリング、バイオマーカーの同定、ハイスループットスクリーニングデータの統合などが含まれます。創薬インフォマティクスは、医薬品開発を加速し、成功の可能性を高めるため、現在の製薬研究において不可欠です。

人工知能（AI）、機械学習、ビッグデータ解析の進歩により、創薬インフォマティクスは楽観的な見通しを立てています。これらの技術は、予測モデリング能力を大幅に向上させ、研究者がより効果的でオーダーメイドの医薬品を開発できるようになると予測されています。オミックスデータ（ゲノミクス、プロテオミクス、メタボロミクス）の統合は、疾病メカニズムのより包括的な知識を可能にし、新たな治療ターゲットの特定につながります。

業界が精密医療を目指す中で、薬剤探索インフォマティクスは、遺伝的・分子的特徴に基づいて特定の患者集団に薬剤候補を調整するのに役立ちます。クラウドコンピューティングの利用拡大により、世界中の研究者がより簡単に共同研究できるようになり、創薬プロセスのスピードアップ、ひいては新たな治療法の開発方法の変革が期待されます。

製薬業界における研究開発費の増加は、創薬インフォマティクス市場を牽引するか？

製薬業界における研究開発費の増加は、創薬インフォマティクス市場を推進すると思われます。製薬企業は2019年に830億米ドルを研究開発に投資しましたが、これは2008年の480億米ドルから大幅に増加しており、イノベーションと新薬の発見への献身を示しています。研究開発に投じられる多額の財源は、創薬プロセスを合理化・改善する高度なインフォマティクス・ソリューションに対する需要の増加を生み出し、研究者は膨大な量のデータをより効率的に分析し、有望な新薬候補を特定し、最終的に新薬の上市までのスケジュールを早めることができます。

個別化医療のニーズの高まりが、創薬インフォマティクス市場を後押しします。2018年にFDAが承認した新治療法の25％（2005年の5％から増加）を占める個別化医療の激増は、ユニークな患者プロファイルに治療を適応させるという業界の献身を示しています。この動向は、遺伝的、環境的、ライフスタイル的側面を含む幅広いデータを適切に分析できる、改良されたインフォマティクス・ツールの重要な必要性を浮き彫りにしています。研究開発者は、こうした高度なインフォマティクス・ソリューションを活用することで、医薬品開発プロセスを合理化し、治療成績を向上させることができ、創薬インフォマティクス市場の今後の成長を後押しすることになります。

高コストは創薬インフォマティクス市場の成長に影響を与えるか？

高コストは創薬インフォマティクス市場の成長に影響を与えると思われます。小規模な製薬企業や新興企業は、高度なインフォマティクス・ツール、データ管理システム、有能な人材に必要な多額の資金を投入することが困難となる可能性があります。このような高コストにより、最先端技術へのアクセスが制限され、画期的なインフォマティクス・ソリューションの導入が遅れる可能性があります。多くの企業が経験している研究開発予算全体の制約により、創薬インフォマティクスへの支出が減少する可能性があり、企業は高度なデータ分析機能よりも重要な支出を優先するため、市場の成長が阻害されます。

標準化の欠如は、創薬インフォマティクス市場の成長に影響を与えます。世界的に認知されたプロトコルやデータ形式がなければ、複数のプラットフォーム間で情報を統合・交換することは困難となり、研究者や研究機関間のコラボレーションが阻害されます。このような断片化は、企業が異種のデータセットやプロセスを統合しようとする際に非効率を招き、最終的に創薬プロセスを遅らせる可能性があります。標準がないため、データの質にばらつきが生じ、正確な知見を得ることが難しくなり、創薬インフォマティクスソリューションへの投資意欲が減退する可能性があります。

目次

第1章 世界の創薬インフォマティクス市場：イントロダクション

• 市場の導入
• 分析範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの分析手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界の創薬インフォマティクス市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析
• 規制の枠組み

第5章 世界の創薬インフォマティクス市場：用途別

• 概要
• 創薬
• 医薬品開発

第6章 世界の創薬インフォマティクス市場：機能別

• 概要
• 配列解析プラットフォーム
• 分子モデリング
• ドッキング
• シーケンス・試験データ管理

第7章 世界の創薬インフォマティクス市場：エンドユーザー別

• 概要
• 製薬・バイオテクノロジー企業
• CRO（医薬品開発業務受託機関）

第8章 世界の創薬インフォマティクス市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 世界のその他の地域

第9章 世界の創薬インフォマティクス市場の競合情勢

• 概要
• 企業市場シェア
• ベンダー情勢
• 主な発展戦略

第10章 企業プロファイル

• Thermo Fisher Scientific, Inc.
• PerkinElmer, Inc.
• Certara, L.P.
• Infosys Limited
• Novo Informatics Pvt. Ltd.
• Collaborative Drug Discovery Inc.
• Selvita
• Charles River Laboratories, Inc.
• Jubilant Life Sciences Ltd.
• IO Informatics, Inc.

第11章 主な動向

• 製品の上市／開発
• 企業合併・買収 (M&A)
• 事業拡大
• 提携・協力

第12章 付録

• 関連分析

Drug Discovery Informatics Market Valuation - 2026-2032

The expanding demand for drug discovery informatics, including the increasing complexity of drug discovery, the desire to accelerate drug development timeframes, and the growing emphasis on customized treatment. Advances in technologies such as genomics, proteomics, and artificial intelligence are allowing researchers to collect and analyze massive amounts of data, increasing the demand for informatics tools to organize and interpret this information. The market size surpass USD 3.41 Billion valued in 2024 to reach a valuation of around USD 7.57 Billion by 2032.

The growing emphasis on creating targeted medicines for particular diseases and patient populations is driving demand for more advanced drug discovery informatics systems. The rising demand for cost-effective and efficient drug discovery informatics is enabling the market grow at a CAGR of 11.57% from 2026 to 2032.

Drug Discovery Informatics Market: Definition/ Overview

Drug Discovery Informatics is the application of computational tools and approaches to improve the process of drug discovery and development. This multidisciplinary discipline uses data management, bioinformatics, cheminformatics, and advanced analytical tools to examine biological data, chemical characteristics, and medication interactions. It helps researchers find prospective medication candidates, forecast their efficacy and safety, and optimize their chemical structures. Applications include virtual compound libraries screening, quantitative structure-activity relationship (QSAR) modeling, biomarker identification, and high-throughput screening data integration. Drug Discovery Informatics is essential in current pharmaceutical research since it accelerates drug development and increases the likelihood of success.

Drug Discovery Informatics is looking optimistic, thanks to advances in artificial intelligence (AI), machine learning, and big data analytics. These technologies are projected to greatly improve predictive modeling skills, enabling researchers to develop more effective and tailored medicines. The integration of omics data (genomics, proteomics, and metabolomics) will allow for a more comprehensive knowledge of disease mechanisms, leading to the identification of new therapeutic targets.

As the industry moves toward precision medicine, medication Discovery Informatics will help tailor medication candidates to specific patient populations based on genetic and molecular characteristics. The growing use of cloud computing will allow researchers around globally to collaborate more easily, speeding up the drug discovery process and, ultimately, changing how new treatments are developed.

Will the Increasing R&D Expenditure in the Pharmaceutical Industry Drive the Drug Discovery Informatics Market?

The increasing R&D spending in the pharmaceutical industry will propel the Drug Discovery Informatics market. Pharmaceutical companies invested USD 83 Billion in R&D in 2019, a significant increase from USD 48 Billion in 2008, demonstrating their dedication to innovation and the discovery of novel medicines. The significant financial resources invested in R&D create an increased demand for advanced informatics solutions that streamline and improve the drug discovery process, allowing researchers to analyze massive amounts of data more efficiently, identify promising drug candidates, and ultimately accelerate the timeline for bringing new drugs to market.

The rising need for personalized medicine will propel the drug discovery informatics market. The enormous increase in personalized medications, which accounted for 25% of all new FDA-approved therapies in 2018 (up from 5% in 2005), demonstrates the industry's dedication to adapting treatments to unique patient profiles. This trend highlights the critical need for improved informatics tools capable of properly analyzing a wide range of data, including genetic, environmental, and lifestyle aspects. Researchers can use these sophisticated informatics solutions to streamline drug development processes and improve treatment outcomes, driving future growth in the drug discovery informatics market.

Will the High Costs Impact the Growth of the Drug Discovery Informatics Market?

High costs will have an impact on the growth of the drug discovery informatics market. Smaller pharmaceutical companies and startups may find it difficult to make the considerable financial commitment required for advanced informatics tools, data management systems, and qualified personnel. These high costs may limit access to cutting-edge technologies, thereby stalling the adoption of breakthrough informatics solutions. The overall R&D budget constraints experienced by many organizations may result in reduced spending on drug discovery informatics, impeding market growth as companies prioritize vital expenditures over advanced data analytics capabilities.

The lack of standardization will have an impact on the growth of the drug discovery informatics market. Without globally acknowledged protocols and data formats, integrating and exchanging information across several platforms becomes difficult, thereby hindering collaboration among researchers and institutions. This fragmentation may result in inefficiencies as businesses attempt to integrate disparate data sets and processes, eventually slowing the drug discovery process. The lack of standards might result in variable data quality, making it difficult to obtain accurate insights and discouraging investment in drug discovery informatics solutions.

Category-Wise Acumens

What Factors Expand the Use of the Drug Discovery Informatics Market?

Sequencing & trial data management is currently the dominant segment in the drug discovery informatics market. The increasing availability of high-throughput sequencing technology will propel the sequencing & trial data management segment. These sophisticated technologies allow researchers to generate massive amounts of genetic data rapidly and inexpensively, greatly improving the ability to perform large-scale investigations and clinical trials. As the volume of sequencing data increases, there is a greater demand for comprehensive data management solutions that can efficiently process, analyze, and interpret this information.

The growth in genome data will propel the sequencing & trial data management segment. As genome sequencing technology evolves, the amount of data generated grows exponentially, necessitating the development of sophisticated data management solutions capable of efficiently storing, processing, and analyzing such huge amounts of information. This demand is driven by the need for researchers and clinicians to incorporate genetic data into their workflows, enabling customized medicine and more targeted therapeutic methods.

What Factors Boost the Use of the Drug Discovery Informatics Market?

Pharmaceutical and biotechnology companies are experiencing rapid growth segment in the drug discovery informatics market. Heavy investment in research and development (R&D) propels the Pharmaceutical & Biotechnology Companies Segment of the Drug Discovery Informatics Market, encouraging innovation and improving the drug discovery process. Pharmaceutical and biotech companies, which spent $83 billion on R&D in 2019, are increasingly looking for advanced informatics solutions to handle and analyze the massive amounts of data created during the discovery phase. This financing enables enterprises to capitalize on data-driven insights, increase candidate screening efficiency, and speed the development of new therapies.

The pharmaceutical & biotechnology companies segment of the drug discovery informatics market is likely to be driven by enhanced efficiency and cost reduction. As more companies use advanced informatics solutions, they can streamline their drug discovery processes, significantly reducing the time and resources required to bring new therapies to market. These efficiencies are accomplished by improving data management, predictive modeling, and automating procedures to decrease manual errors and redundancies. By cutting operational costs and increasing efficiency, pharmaceutical and biotechnology companies may devote more resources to innovation and competitive advantage, driving up demand for drug discovery informatics tools.

Country/Region-wise Acumens

Will the Advanced Research Institutions in the North American Region Propel the Drug Discovery Informatics Market?

North America leads the drug discovery informatics market. Advanced research institutions in North America will expand the drug discovery informatics market. These institutions are essential to encouraging innovation and growth, as indicated by the National Science Foundation's estimate that U.S. colleges and universities will invest USD 89.9 Billion in research and development in fiscal year 2021, with life sciences accounting for 56% of this expenditure. The National Institutes of Health (NIH) is further supporting this growth with a USD 39.2 Billion investment in medical research for fiscal year 2023, to improve drug discovery technologies and leverage artificial intelligence to potentially reduce early-stage drug development costs by 30-50% while shortening timelines.

The strong pharmaceutical and biotechnology industry in North America will power the drug discovery informatics market. In 2021, the U.S. biopharmaceutical industry would invest around USD 102.3 Billion in research and development, increasing need for advanced informatics tools to improve R&D efficiency and productivity. The FDA announced that 37 innovative medications were authorized in 2022, with many relying on sophisticated informatics and computational methodologies. By 2025, it is expected that more than half of new drug applications will use model-based research. The presence of over 6,441 biotech businesses actively embracing AI and machine learning, together with the NIH's funding of USD 1.5 Billion for biomedical informatics in 2023, demonstrates the robust investment and innovation that will drive the growth of the drug discovery informatics market.

Will the Rising Awareness of Drug Discovery Informatics Lead the Asian Pacific Region for the Drug Discovery Informatics Market?

The Asia-Pacific region is experiencing the fastest growth in the drug discovery informatics market. The growing awareness of drug discovery informatics is likely to propel the drug discovery informatics market in the Asia-Pacific region. Increased investments in drug discovery technology, particularly in nations such as India, which wants to have a USD 150 Billion biotech industry by 2025, and China, where AI-powered drug discovery companies have risen tenfold since 2018, highlight this trend. role in advancing the development of novel treatments to satisfy a variety of health needs.

The cost-effective labor in the Asia-Pacific region is a major driver of the drug discovery informatics market. The average salary for skilled biotechnology professionals in India is just $15,000, compared to $85,000 in the United States, making it financially appealing for pharmaceutical corporations to set up R&D units there. Since 2020, the number of bioinformatics specialists in the region has increased by 35%, with more growth expected. Outsourcing drug development efforts to Asia-Pacific can lower R&D costs by 25-45%, prompting more than 60% of global pharmaceutical corporations to build operations in the region by 2025. The combination of low-cost skilled labor and an expanding talent pool puts Asia-Pacific as a major participant in drug discovery informatics.

Competitive Landscape

The drug discovery informatics market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the drug discovery informatics market include:

• Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Certara, L.P., Infosys Limited, Novo Informatics Pvt. Ltd., Collaborative Drug Discovery, Inc., Selvita, Charles River Laboratories, Inc., Jubilant Life Sciences Ltd., IO Informatics, Inc., GVK Biosciences Private Limited, Dassault Systemes.

Latest Developments

• In April 2024, Sapio Sciences, the science-aware lab informatics platform, now supports multimodal registration. It combines small-molecule, large-molecule, and multimodal discovery methods, including entity registration, into a single platform.
• In February 2023, Insilico Medicine, a clinical-stage end-to-end generative artificial intelligence (Al)-driven drug discovery business, revealed that it has received the FDA Orphan Drug Designation for its AI-discovered and designed medication for idiopathic pulmonary fibrosis.

Drug Discovery Informatics Market, By Category

• Application
• Drug Discovery
• Drug Development
• Function
• Sequence Analysis Platforms
• Molecular Modelling
• Docking
• Sequencing & Trial Data Management
• End-User
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Region
• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DRUG DISCOVERY INFORMATICS MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DRUG DISCOVERY INFORMATICS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Drug Discovery
• 5.3 Drug Development

6 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY FUNCTION

• 6.1 Overview
• 6.2 Sequence Analysis Platforms
• 6.3 Molecular Modelling
• 6.4 Docking
• 6.5 Sequencing & Trial Data Management

7 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY END-USER

• 7.1 Overview
• 7.2 Pharmaceutical & Biotechnology Companies
• 7.3 Contract Research Organizations

8 GLOBAL DRUG DISCOVERY INFORMATICS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Argentina
• 8.6 Rest of the World

9 GLOBAL DRUG DISCOVERY INFORMATICS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Thermo Fisher Scientific, Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 PerkinElmer, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Certara, L.P.
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Infosys Limited
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Novo Informatics Pvt. Ltd.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Collaborative Drug Discovery Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Selvita
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Charles River Laboratories, Inc.
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Jubilant Life Sciences Ltd.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 IO Informatics, Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 APPENDIX

• 12.1 Related Research